Status:
COMPLETED
Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders
Lead Sponsor:
Gruppo Italiano Studio Linfomi
Conditions:
Relapsed or Refractory Chronic Lymphoproliferative Disorders
Eligibility:
All Genders
18+ years
Brief Summary
This retrospective study collects and evaluates the clinical experience reached in Italy on the use of bendamustine alone or combined with rituximab as treatment of patients with relapsed or refractor...
Eligibility Criteria
Inclusion
- patients with relapsed or refractory chronic lymphoproliferative disorders
- salvage treatment with bendamustine +/- rituximab
- age ≥ 18 years
Exclusion
- previous treatment with bendamustine
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT01224769
Start Date
September 1 2005
End Date
December 1 2009
Last Update
October 21 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gruppo Italiano Studio Linfomi
Modena, Italy, 41124